Peng Dong, Xiang Ying-Chun, Tang Kai-Lin, Qiu Yan-Yu
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China.
Biomed Rep. 2023 Oct 19;19(6):97. doi: 10.3892/br.2023.1679. eCollection 2023 Dec.
The purpose of the current study was to compare the outcomes of patients with gastric cancer (GC) between the type 2 diabetes mellitus (T2DM) group and the non-T2DM group. The PubMed, Embase and Cochrane Library databases were searched from inception to March 8, 2022, to identify propensity score matching (PSM) studies that analyzed the effect of T2DM on the outcomes of patients with GC. Total complications, overall survival (OS), disease-free survival (DFS) and cancer-specific survival (CSS) were compared between the T2DM group and the non-T2DM group. A total of four PSM studies with 834 patients were included in the current study. There were 311 and 523 patients in the T2DM group and the non-T2DM group, respectively. Baseline characteristics of the two groups were adjusted with PSM in all the four studies, however, no significant difference was found in baseline characteristics (P>0.05). DFS was significantly worse in the T2DM group compared with that in the non-T2DM group [hazard ratio (HR), 1.45; 95% confidence interval (CI), 1.10-1.90; P=0.007)]. However, after pooling up the data, there was no significant difference between the T2DM group and the non-T2DM group in terms of OS (HR, 1.41; 95% CI, 0.92-2.16; P=0.11), CSS (HR, 1.29; 95% CI, 0.92-1.81; P=0.14) and total complications (odds ratio, 1.01; 95% CI, 0.64-1.60; P=0.95). Patients with GC and T2DM are associated with poor DFS. However, there were no significant differences between the T2DM group and the non-T2DM group in terms of OS, CSS and total complications.
本研究的目的是比较2型糖尿病（T2DM）组和非T2DM组胃癌（GC）患者的预后。检索了PubMed、Embase和Cochrane图书馆数据库，检索时间从数据库建立至2022年3月8日，以识别分析T2DM对GC患者预后影响的倾向评分匹配（PSM）研究。比较了T2DM组和非T2DM组的总并发症、总生存期（OS）、无病生存期（DFS）和癌症特异性生存期（CSS）。本研究共纳入4项PSM研究，涉及834例患者。T2DM组和非T2DM组分别有311例和523例患者。在所有4项研究中，两组的基线特征均通过PSM进行了调整，但基线特征无显著差异（P>0.05）。与非T2DM组相比，T2DM组的DFS显著更差[风险比（HR），1.45；95%置信区间（CI），1.10 - 1.90；P = 0.007]。然而，汇总数据后，T2DM组和非T2DM组在OS（HR，1.41；95% CI，0.92 - 2.16；P = 0.11）、CSS（HR，1.29；95% CI，0.92 - 1.81；P = 0.14）和总并发症（优势比，1.01；95% CI，0.64 - 1.60；P = 0.95）方面无显著差异。GC合并T2DM的患者DFS较差。然而，T2DM组和非T2DM组在OS、CSS和总并发症方面无显著差异。
